AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN – Free Report) in a report issued on ...

Check the time stamp on this data. Updated AI-Generated Signals for Astrazeneca Plc (AZN) available here: AZN.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

For example, during the event, AstraZeneca shared promising early data for its oral GLP-1 candidate, AZD5004, and told Fierce ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

The company confirmed that Leon Wang, head of its Chinese arm, was being detained while two other executives, as well as two ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...